Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

GBM4EPI Development of glioblastoma and blood-tumour barrier models for investigating the combination therapy of anticancer agents and efflux pump inhibitors

Coordinator
Universita Degli Studi Di Torino, Italy
Runs
1 January 2025 to 31 December 2026
Status
Running
EU funding
€173k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101151942

What the project is doing

In the project's own words, from its summary on CORDIS.

Glioblastoma (GBM) remains the most common malignant primary brain tumour with a median survival <2 years. One of the reasons for the failure of GBM therapy involves limited drug access to the tumour site due to the presence of the blood-brain barrier (BBB)/blood-tumour barrier (BTB). Although these barriers differ, they share some common features, such as tight junction (TJ) and efflux proteins of the ATP-binding (ABC) cassette superfamily that regulate drug access to the brain parenchyma.

Similarly, efflux proteins have been identified in GBM that form an additional barrier. In the proposed research, five-dimensional (5D) models of GBM-BTB will take into account all characteristics essential to approach more realistic in vivo conditions, mainly the integration of glioblastoma stem cell (GSC) derived pericytes into BTB, and the incorporation of varying degrees of tumour cell differentiation (from GCS to well differentiated cells) showing a different degree of intrinsic chemoresistance.

Additionally, microfluidic models reproducing blood flow will add a temporal and dynamic dimension (""5D models""). Once the models are established and compared with static ones, the effect of anticancer therapy and efflux protein inhibitors (EPIs) will be verified in terms of TJ and ABC protein expression using qRT-PCR and confocal microscopy. The identified combination therapy of anticancer agents and EPIs will lead to validation in patient-derived GMB-BTB models with different molecular profiles and degrees of resistance, with the goal of personalised medicine.

By working on this project, the researcher will gain valuable experience that is needed to address the challenges associated with the treatment of therapy-resistant tumours. In general, this project may provide a more realistic view of the potential effect of combination therapy under in vivo conditions. This could ultimately expand the treatment options for cancer patients and increase their chances of survival.""

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di TorinoTorinoItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI